Physician profile
Amaranta Craig
NPI 1881004281
$8,434.96
in general payments reported to CMS, 2019-2025
20 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,091 · 2022: $1,172 · 2023: $1,831 · 2024: $4,217 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,540 · Grant: $1,711 · Education: $1,000 · Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,539.70 |
| Grant | $1,710.50 |
| Education | $1,000.00 |
| Food and Beverage | $921.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,597.66 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,952.82 | 2021-2024 | Lynparza, Enhertu, Tagrisso |
| Eisai INC. | $1,075.03 | 2021-2024 | |
| Abbvie INC. | $124.19 | 2025 | |
| Genmab U.S., INC. | $107.47 | 2022-2024 | Epkinly |
| Glaxosmithkline, LLC. | $99.67 | 2021-2024 | Zejula, Jemperli |
| Novartis Pharmaceuticals Corporation | $78.33 | 2024 | |
| Janssen Biotech, INC. | $66.02 | 2023-2024 | Darzalex, Tecvayli, Talvey |
| Merck Sharp & Dohme LLC | $55.72 | 2024 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $50.62 | 2024 | |
| Genzyme Corporation | $39.56 | 2024 | |
| Seagen INC. | $30.68 | 2023 | Adcetris |
| Tersera Therapeutics LLC | $24.01 | 2024 | Zoladex |
| Incyte Corporation | $21.21 | 2024 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $20.98 | 2024 | Alunbrig |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $19.54 | 2024 | Enhertu |
| Springworks Therapeutics, INC. | $19.42 | 2024 | Ogsiveo |
| Sobi, INC | $19.19 | 2024 | |
| Tempus Ai, INC | $17.79 | 2024 | |
| Jazz Pharmaceuticals INC. | $15.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amaranta Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.